Substituted benzene compounds

• US 9,089,575 B2
• Filed: 03/05/2015
• Issued: 07/28/2015
• Est. Priority Date: 10/15/2012
• Status: Active Grant

• Current Assignee: Epizyme, Inc. (Ipsen Sa)
• Original Assignee: Epizyme, Inc. (Ipsen Sa)
• Inventors: Kuntz, Kevin Wayne, Campbell, John Emmerson, Seki, Masashi
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US14/639,878
• Publication Number:
  US 20150174136A1
• Time in Patent Office: 145 Days
• Field of Search: 514/235.5, 514/351, 514/318, 546/300, 546/194, 544/131
• US Class Current: 1/1
• CPC Class Codes: A61K 31/4412 having oxo groups directly attached to the heterocyclic ring
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 31/5375 1,4-Oxazines, e.g. morpholine
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07D 213/64 attached in position 2 or 6
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/14 containing three or more hetero rings

Abstract

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Claims

1. A method of treating cancer comprising administering to a human subject in need thereof a therapeutically effective amount of

2. The method of claim 1, wherein the cancer is lymphoma or malignant rhabdoid tumor.

3. The method of claim 2, wherein the cancer is lymphoma.

4. The method of claim 3, wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin'"'"'s lymphoma (NHL), and follicular lymphoma.

5. The method of claim 2, wherein the cancer is malignant rhabdoid tumor.

6. The method of claim 1, wherein the compound is

7. A method of treating cancer comprising administering to a human subject in need thereof a therapeutically effective amount of

8. The method of claim 7, wherein the cancer is lymphoma or malignant rhabdoid tumor.

9. The method of claim 8, wherein the cancer is lymphoma.

10. The method of claim 9, wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin'"'"'s lymphoma (NHL), and follicular lymphoma.

11. The method of claim 8, wherein the cancer is malignant rhabdoid tumor.

12. A method of treating cancer comprising administering to a human subject in need thereof a therapeutically effective amount of

13. The method of claim 12, wherein the cancer is lymphoma or malignant rhabdoid tumor.

14. The method of claim 13, wherein the cancer is lymphoma.

15. The method of claim 14, wherein the lymphoma is selected from diffuse large B-cell lymphoma (DLBCL), non-Hodgkin'"'"'s lymphoma (NHL), and follicular lymphoma.

16. The method of claim 12, wherein the cancer is malignant rhabdoid tumor.